<p>As we now have access to Inavolisib via a ROCHE sponsored PSP for the first line treatment of endocrine resistant HR+ HER2- PIK3CA altered breast cancer progressing on or after adjuvant endocrine therapy, Dr. Kasia Jerzak takes us through the regimen, its practical use and efficacy and toxicity management.</p>

As we now have access to Inavolisib via a ROCHE sponsored PSP for the first line treatment of endocrine resistant HR+ HER2- PIK3CA altered breast cancer progressing on or after adjuvant endocrine therapy, Dr. Kasia Jerzak takes us through the regimen, its practical use and efficacy and toxicity management.

Inavolisib in Endocrine Resistant PIK3CA Mutated HR+, HER2- Breast Cancer with Dr. Kasia Jerzak

OncologyEducation, in partnership with Dr. Shaqil Kassam, is proud to present the MedOncNow podcast.

Hosted by Dr. Kassam, MedOncNow offers critical insights on hot topics in medical oncology. From emerging therapies to new standards of care, MedOncNow features discussions with leading oncology experts who share relevant, practical information you can incorporate into your practice.

Medicine

Health & Fitness

OncologyEducation, in partnership with Dr. Shaqil Kassam, is proud to present the MedOncNow podcast. Hosted by Dr. Kassam, MedOncNow offers critical insights on hot topics in medical oncology. From emerging therapies to new standards of care, MedOncNow features discussions with leading oncology experts who share relevant, practical information you can incorporate into your practice.

Share Inavolisib in Endocrine Resistant PIK3CA Mutated HR+, HER2- Breast Cancer with Dr. Kasia Jerzak

Sign up to save your podcasts

Inavolisib in Endocrine Resistant PIK3CA Mutated HR+, HER2- Breast Cancer with Dr. Kasia Jerzak

Inavolisib in Endocrine Resistant PIK3CA Mutated HR+, HER2- Breast Cancer with Dr. Kasia Jerzak